# Quercetin (Senolytic Bioflavonoid) - Clinical Longevity Review & Consensus Audit > **Consensus Verdict**: Quercetin is a prominent plant polyphenol that inhibits PI3K-Akt, Bcl-w, and HIF-1alpha anti-apoptotic networks in senescent cells. When combined with dasatinib (D+Q), it established the first proof-of-concept for pharmacological senescent cell clearance in humans, reducing p16- and p21-positive cells in diabetic kidney disease and improving walking endurance in idiopathic pulmonary fibrosis. ## 1. Executive Summary & Scores - **Longevity Evidence Score**: **86/100** - **Evidence Quality Tier**: **silver** - **Human Clinical Evidence Strength**: 88/100 - **Primary Longevity Classification**: supplements - **Safety Margin Score**: 92/100 (Higher is safer) - **Time Burden**: ~1 minutes/day - **Estimated Monthly Cost**: inexpensive - **Adherence Friction**: 1/10 (Lower is easier to sustain) --- ## 2. Biological Mechanisms of Action Quercetin + Dasatinib Senolytic StackThe foundational senolytic protocol combines Dasatinib (a tyrosine kinase inhibitor originally used for leukemia) and Quercetin (a plant flavonol). This combination was identified through hypothesis-driven bioinformatics as a potent dual-inhibitor of SCAPs. Dasatinib primarily targets ephrins and the PI3K/AKT pathway, effectively clearing senescent adipocytes and preadipocytes, while Quercetin targets the Bcl-2 family and HIF-1α, clearing senescent endothelial cells and bone marrow stem cells. Clinical trials demonstrate that intermittent administration is sufficient to induce a "hit-and-run" clearance of senescent cells, significantly reducing the SASP burden without causing long-term immunosuppression7. The standard protocol utilizes a 1,000mg dose of Quercetin alongside 100mg of Dasatinib for two consecutive days per month. In human trials, including those targeting idiopathic pulmonary fibrosis and early-stage Alzheimer's disease, this intermittent dosing profile has demonstrated an acceptable safety profile while providing favorable target engagement within the central nervous system, as verified by cerebrospinal fluid penetration7. Preclinical studies utilizing older mice have shown that clearing these cells with D+Q improves physical function, ameliorates intervertebral disc degeneration, and diminishes neuroinflammation7. --- ## 3. Canonical Longevity Vector Impacts (The 8 Longevity Pillars) - **Heart Health & Endothelial Function**: **60/100** [Rank #97 of 133 in Heart] - Effect: Moderate (Enhanced Endothelial Flow-Mediated Dilation) - Mechanism: Scavenges superoxide radicals to uncouple eNOS oxidation, sustaining vascular nitric oxide synthesis and improving arterial compliance. - **Brain Longevity & Neuroprotection**: **54/100** [Rank #119 of 141 in Brain] - Effect: Moderate (Attenuates neurovascular inflammation) - Mechanism: Protects blood-brain barrier tight junctions from oxidative degradation and inhibits microglial NF-kappaB activation. - **Metabolic Flexibility & Glycemic Control**: **52/100** [Rank #96 of 129 in Metabolic] - Effect: Moderate (Mild AMPK activation and hepatic lipid clearance) - Mechanism: Mildly stimulates AMPK phosphorylation in hepatocytes, dampening de novo lipogenesis and improving glycemic homeostasis. - **Cancer Defense & DNA Repair**: **48/100** [Rank #47 of 120 in Cancer Defense] - Effect: Moderate (Inhibits pro-survival oncogenic kinases and SASP) - Mechanism: Suppresses angiogenesis-promoting SASP factors and downregulates survival signaling in pre-malignant transformed cells. - **Endocrine & Anabolic Balance**: **0/100** [Rank #106 of 120 in Endocrine] - Effect: Neutral - Mechanism: Bioflavonoid with neutral impact on circulating serum testosterone. - **Chronic Inflammation Reduction**: **82/100** [Rank #35 of 126 in Inflammation] - Effect: Strong (-28% Circulating SASP Biomarkers in Humans) - Mechanism: Reduces circulating inflammatory SASP secretome and improves functional 6-minute walk distance in clinical cohorts with fibrotic lung pathology. - **Bone Density & Connective Matrix**: **30/100** [Rank #83 of 142 in Bone Matrix] - Effect: Mild (Reduces inflammatory osteoclast differentiation) - Mechanism: Dampens RANKL-induced osteoclastogenesis through NF-kappaB pathway suppression. - **Cellular Longevity & Autophagy**: **88/100** [Rank #37 of 131 in Cellular] - Effect: Strong (First-in-Human Senolytic Demonstration; Clears Adipose p16+ Cells) - Mechanism: Inhibits the PI3K-Akt and Bcl-w senescent survival nodes, demonstrating proven senolytic clearance in human adipose tissue biopsies. --- ## 4. Practical Protocol & Administration Guidelines - **Standard Clinical Dosage**: 500-1000mg - **Recommended Timing**: With Meals - **Administration Type**: supplement - **Recommended Biomarkers to Monitor**: immune_resilience, chronic_inflammation, soreness, heart_health, bone_density, testosterone --- ## 5. Safety, Contraindications & Drug Interactions - **Contraindications**: Severe renal impairment, Hypersensitivity to flavonoids - **Safety Profile**: low_risk - Mild stomach upset if taken on an empty stomach --- ## 6. Peer-Reviewed Human Clinical Trials & Key PMIDs 1. **Quercetin ingestion does not alter muscle glycogen utilization but attenuates systemic oxidative stress** [PMID: 18043004] - Link: https://pubmed.ncbi.nlm.nih.gov/18043004/ 2. **Quercetin improves endothelial function and flow-mediated dilation in humans** [PMID: 23321588] - Link: https://pubmed.ncbi.nlm.nih.gov/23321588/ 3. **Quercetin reduces illness but not muscle damage in athletes: A double-blind RCT** [PMID: 20561576] - Link: https://pubmed.ncbi.nlm.nih.gov/20561576/ 4. **Senolytics decrease senescent cells in humans: Preliminary report from a clinical trial of Dasatinib plus Quercetin** [PMID: 31542391] - Link: https://pubmed.ncbi.nlm.nih.gov/31542391/ 5. **Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study** [PMID: 30616998] - Link: https://pubmed.ncbi.nlm.nih.gov/30616998/ 6. **Quercetin supplementation reduces inflammatory biomarkers in women with rheumatoid arthritis** [PMID: 28068200] - Link: https://pubmed.ncbi.nlm.nih.gov/28068200/ --- ## 7. Canonical Citation & Web Verification - **Official Web Review**: [Quercetin (Senolytic Bioflavonoid) on LongevityReviews](https://longevityreviews.org/modalities/quercetin) - **Last Evidence Calibration**: 2026-09-09 - **Review Policy**: 0% sponsored placements, independent peer-reviewed consensus.